Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors

A method for treating or delaying progression of a melanoma that is resistant to a B-raf antagonist in an individual, the method comprising administering to the individual an effective amount of a PD-L1 binding antagonist and a MEK inhibitor, wherein:

• the individual has been previously treated with the B-raf antagonist for melanoma and the melanoma is resistant to the B-raf antagonist,
• the MEK inhibitor is GDC-0973 or a pharmaceutically acceptable salt or solvate thereof, and
• the PD-L1 antagonist is an anti-PD-L1 antibody comprising a heavy chain comprising HVR-H1 sequence of SEQ ID NO:
• 15, HVR-H2 sequence of SEQ ID NO:
• 16, and HVR-H3 sequence of SEQ ID NO:
• 3;
• and a light chain comprising HVR-L1 sequence of SEQ ID NO:
• 17, HVR-L2 sequence of SEQ ID NO:
• 18, and HVR-L3 sequence of SEQ ID NO:
• 19.